Chenodeoxycholic acid restrains tumor growth via TGR5-dependent type 1 dendritic cells cross-priming.
Bile acids enhance anti-tumor immunity via dendritic cells, suggesting diet or microbiome changes could boost immunotherapy.
This study published in Signal Transduction and Targeted Therapy reveals that the bile acid CDCA suppresses tumor growth by activating TGR5 on cDC1 dendritic cells to enhance CD8+ T cell cross-priming, establishing a novel bile acid-immunity axis. The finding suggests gut microbiome-derived bile acids could potentiate immunotherapy responses, with potential for dietary or microbiome-based combination strategies.
What the study was
- Study design
- Preclinical mechanistic study
- Population
- Mouse tumor models for bile acid-immune checkpoint interaction
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Signal transduction and targeted therapy
Why it surfaced
Signal Transduction and Targeted Therapy (IF ~38) publication of novel bile acid-immune checkpoint mechanism. Score capped at 5 (non-human preclinical). PROMISING_PRELIMINARY for microbiome-immune-cancer axis.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.